TW202525841A - 識別p53中之r175h或y220c突變之t細胞受體 - Google Patents

識別p53中之r175h或y220c突變之t細胞受體 Download PDF

Info

Publication number
TW202525841A
TW202525841A TW114110844A TW114110844A TW202525841A TW 202525841 A TW202525841 A TW 202525841A TW 114110844 A TW114110844 A TW 114110844A TW 114110844 A TW114110844 A TW 114110844A TW 202525841 A TW202525841 A TW 202525841A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
polypeptide chain
leu
Prior art date
Application number
TW114110844A
Other languages
English (en)
Chinese (zh)
Inventor
德魯 C 丹尼格
帕里薩 馬利扎德
史帝文 A 羅森伯格
安娜 帕塞托
Original Assignee
美國衛生與公眾服務部
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國衛生與公眾服務部 filed Critical 美國衛生與公眾服務部
Publication of TW202525841A publication Critical patent/TW202525841A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
TW114110844A 2019-06-27 2020-06-26 識別p53中之r175h或y220c突變之t細胞受體 TW202525841A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867619P 2019-06-27 2019-06-27
US62/867,619 2019-06-27

Publications (1)

Publication Number Publication Date
TW202525841A true TW202525841A (zh) 2025-07-01

Family

ID=71662353

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114110844A TW202525841A (zh) 2019-06-27 2020-06-26 識別p53中之r175h或y220c突變之t細胞受體
TW109121744A TWI908730B (zh) 2019-06-27 2020-06-26 識別p53中之r175h或y220c突變之t細胞受體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109121744A TWI908730B (zh) 2019-06-27 2020-06-26 識別p53中之r175h或y220c突變之t細胞受體

Country Status (11)

Country Link
US (1) US12479902B2 (cg-RX-API-DMAC7.html)
EP (1) EP3990481A1 (cg-RX-API-DMAC7.html)
JP (2) JP7635165B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220047969A (cg-RX-API-DMAC7.html)
CN (1) CN114341171A (cg-RX-API-DMAC7.html)
AU (1) AU2020308004B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026408A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144070A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021015877A (cg-RX-API-DMAC7.html)
TW (2) TW202525841A (cg-RX-API-DMAC7.html)
WO (1) WO2020264269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022232599A1 (en) * 2021-04-30 2022-11-03 Regents Of The University Of Minnesota Mesothelin-specific t cell receptors and methods of using same
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
EP4334340A1 (en) * 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023060195A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2024076692A1 (en) * 2022-10-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as p53 acetylators
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2024220520A2 (en) * 2023-04-21 2024-10-24 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL273515B2 (en) * 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法
CN107748893A (zh) * 2017-09-29 2018-03-02 阿里巴巴集团控股有限公司 提升车辆定损图像识别结果的方法、装置及服务器
EP4334340A1 (en) 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53

Also Published As

Publication number Publication date
EP3990481A1 (en) 2022-05-04
US12479902B2 (en) 2025-11-25
MX2026003696A (es) 2026-06-01
BR112021026408A2 (pt) 2022-02-08
WO2020264269A1 (en) 2020-12-30
KR20220047969A (ko) 2022-04-19
MX2021015877A (es) 2022-04-18
TWI908730B (zh) 2025-12-21
JP2025081413A (ja) 2025-05-27
US20220332785A1 (en) 2022-10-20
AU2020308004A1 (en) 2022-02-03
AU2020308004B2 (en) 2026-03-19
TW202108609A (zh) 2021-03-01
CN114341171A (zh) 2022-04-12
JP7635165B2 (ja) 2025-02-25
JP2022538148A (ja) 2022-08-31
CA3144070A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
TWI908730B (zh) 識別p53中之r175h或y220c突變之t細胞受體
US11466071B2 (en) HLA class I-restricted t cell receptors against mutated RAS
US11352410B2 (en) Anti-KK-LC-1 T cell receptors
EP3901169B1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
US20240254190A1 (en) T cell receptors recognizing c135y, r175h, or m237i mutation in p53
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
US20230365649A1 (en) Hla class ii-restricted dq t cell receptors against ras with g13d mutation
US12577286B2 (en) T cell receptors which recognize mutated EGFR
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體
US20230257440A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12v mutation
RU2830061C2 (ru) T-клеточные рецепторы, распознающие мутацию r175h или y220c в p53
US20240190940A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras